Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
attrition, ay, bid, blockade, contradictory, corroborated, Embedded, ERC, exit, fashion, fifteen, hand, hereunder, hierarchy, IL, illiquid, implicit, inflow, Inline, maker, marked, negate, orderly, outflow, overdue, piece, plasma, room, sophisticated, stability, Taxpayer, temperature, unexercised, unobservable, wage
Removed:
amounted, AP, applied, ASC, averse, Bayer, borrowing, calculate, Codification, community, consortium, disclose, disrupt, duration, Eaglet, element, EPS, explore, extinguishment, fact, formed, imputed, IP, Jersey, joint, lender, lent, minimal, modification, noting, Patheon, penny, PIPE, polysorb, premium, reluctant, replacing, Roth, seasoned, seize, SPA, steady, steering, Subordination, surfactant, tangible, terminating, unamortized, unconsolidated, Vivo
Filing tables
Filing exhibits
Related press release
ACUR similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Acura Pharmaceuticals, Inc.
Palatine, Illinois
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-256677, 333-221645, 333-213017, 333-195612, and 333-151620) of Acura Pharmaceuticals, Inc. of our report dated June 30, 2023, relating to the consolidated financial statements which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
Chicago, Illinois
June 30, 2023